{"schema_version":"1","generated_at":"2026-11-04T09:45:20.335Z","data_as_of":null,"url":"https://www.findmykol.com/kol/natalie-galanina","json_url":"https://www.findmykol.com/kol/natalie-galanina/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"natalie-galanina","name":"Natalie Galanina","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Pittsburgh Medical Center","institution_url":"https://www.findmykol.com/institution/university-of-pittsburgh-medical-center","city":"Pittsburgh","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1235372855","orcid":"0000-0001-8858-3260","openalex":"A5085031013"},"summary":"Natalie Galanina is an Oncology physician affiliated with University of Pittsburgh Medical Center. OpenAlex indexes 46 publications with 966 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":46,"cited_by_count":966,"h_index":11,"latest_activity_year":2026,"source":"works"},"trials":{"count":1,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06767956","title":"Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy","phase":"PHASE1/PHASE2","status":"WITHDRAWN","role":"Overall official","sponsor":"University of Pittsburgh","source_url":"https://clinicaltrials.gov/study/NCT06767956","trial_url":"https://www.findmykol.com/trial/NCT06767956"},{"nct":"NCT03955276","title":"An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)","status":"TERMINATED","role":"Overall official","sponsor":"University of California, San Diego","source_url":"https://clinicaltrials.gov/study/NCT03955276","trial_url":"https://www.findmykol.com/trial/NCT03955276"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":6,"shown":3,"withheld":3,"rows":[{"payer":"Bristol Myers Squibb","program_year":2025,"amount_usd":73113.75,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1235372855"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2024,"amount_usd":2865,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1235372855"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2024,"amount_usd":16.81,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1235372855"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1235372855","source":"payments"},"publications":{"total":46,"shown":5,"withheld":41,"matched_by":"OpenAlex author record","recent":[{"title":"ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma","year":2026,"journal":"Blood Neoplasia","source_url":"https://doi.org/10.1016/j.bneo.2026.100250","status":"verified"},{"title":"ABCL-573: ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)02574-7","status":"verified"},{"title":"POSTER: ABCL-573: ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)01103-1","status":"verified"},{"title":"Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-281","status":"verified"},{"title":"853 | CTEP TRIAL 10590, NORM: NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA PATIENTS TREATED IN A RANDOMIZED PHASE II TRIAL WITH EITHER RITUXIMAB OR MOSUNETUZUMAB","year":2025,"journal":"Hematological Oncology","source_url":"https://doi.org/10.1002/hon.70096_853","status":"verified"}],"source":"works"},"contact":{"address_1":"5115 CENTRE AVE","city":"Pittsburgh","state":"PA","zip":"152321301","phone":"415-572-9678","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1235372855","source":"identity"},"similar":[{"name":"Lawrence Wechsler","slug":"lawrence-wechsler","institution":"University of Pittsburgh Medical Center","specialty":"Neurology","url":"https://www.findmykol.com/kol/lawrence-wechsler","json_url":"https://www.findmykol.com/kol/lawrence-wechsler/profile.json"},{"name":"Michel Makaroun","slug":"michel-makaroun","institution":"University of Pittsburgh Medical Center","specialty":"Vascular Surgery","url":"https://www.findmykol.com/kol/michel-makaroun","json_url":"https://www.findmykol.com/kol/michel-makaroun/profile.json"},{"name":"David Gaieski","slug":"david-gaieski","institution":"University of Pittsburgh Medical Center","specialty":"Emergency Medicine","url":"https://www.findmykol.com/kol/david-gaieski","json_url":"https://www.findmykol.com/kol/david-gaieski/profile.json"},{"name":"Alessandro Furlan","slug":"alessandro-furlan","institution":"University of Pittsburgh Medical Center","specialty":"Diagnostic Radiology","url":"https://www.findmykol.com/kol/alessandro-furlan","json_url":"https://www.findmykol.com/kol/alessandro-furlan/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":3,"publications":41}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-06-20","provider_certified":"2023-03-03","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}